BDNF and Neurotrophic Signaling in Peptide Research

Brain-derived neurotrophic factor was identified in 1982 as the second member of the neurotrophin family, after nerve growth factor, and it has since become one of the most studied molecules in neuroscience. The reason is scope: BDNF signaling touches neuronal survival during development, synapse formation, the strengthening of connections that underlies learning, and the response of the brain to injury and stress. Almost every hypothesis about how a compound might protect neurons or improve cognition passes at some point through BDNF. This note explains the pathway for researchers who work with peptides, sets out how peptides have been studied in relation to it, and flags the measurement problems that make much of the popular literature on “boosting BDNF” unreliable.

The neurotrophin family and its receptors

Neurotrophins are small secreted proteins, NGF, BDNF, NT-3 and NT-4/5, that bind two classes of receptor. The Trk receptors are tyrosine kinases with ligand preferences: NGF binds TrkA, BDNF and NT-4/5 bind TrkB, and NT-3 binds TrkC. All neurotrophins also bind the p75 neurotrophin receptor with lower affinity. The Trk receptors generally signal survival and growth; p75 can signal survival or death depending on its partners and the form of ligand it encounters.¹

BDNF is synthesized as a precursor, pro-BDNF, and cleaved to mature BDNF either inside the cell or after secretion. This matters because pro-BDNF and mature BDNF have opposite effects: mature BDNF acting on TrkB promotes long-term potentiation and dendritic growth, while pro-BDNF acting on p75 with its co-receptor sortilin promotes long-term depression, synaptic pruning and, in some contexts, apoptosis. The balance between the two forms is regulated by proteases including tissue plasminogen activator and plasmin. A statement that a compound “raises BDNF” is incomplete unless it says which form.

TrkB signaling and synaptic plasticity

When mature BDNF binds TrkB, the receptor dimerizes and autophosphorylates, recruiting three main downstream cascades: the PI3K–Akt pathway, associated with survival; the Ras–MAPK/ERK pathway, associated with growth and differentiation; and the PLCγ pathway, which raises intracellular calcium and activates CaMKII and CREB. CREB in turn drives transcription of BDNF itself, creating a positive feedback loop that is central to how activity strengthens synapses.¹

The link to memory is not theoretical. BDNF release is activity-dependent, and blocking TrkB signaling impairs late-phase long-term potentiation in hippocampal slices. In humans, the best evidence comes from genetics: a common variant, Val66Met, substitutes methionine for valine in the pro-domain and impairs activity-dependent secretion of BDNF. Egan and colleagues showed in 2003 that Met carriers had poorer episodic memory and altered hippocampal activation on functional imaging,² a finding replicated by Hariri and colleagues the same year.³ The effect sizes are modest, but the studies established that variation in BDNF handling has measurable consequences in human cognition.

BDNF is less a switch than a thermostat: the brain sets it locally, in response to use, and any intervention has to work through that regulation rather than around it.

What changes BDNF, and how well we know it

The most robust modulator of BDNF is physical activity. Szuhany and colleagues’ meta-analysis of exercise studies found that a single session raised peripheral BDNF and that regular training amplified the acute response, with a moderate effect size.⁴ Antidepressant drugs, ketamine and electroconvulsive therapy also increase BDNF expression in animal models, and the “neurotrophic hypothesis” of depression, that low BDNF in hippocampus and prefrontal cortex contributes to the disorder and that treatments work partly by restoring it, rests on a large body of preclinical and post-mortem evidence, reviewed by Bathina and Das.¹ Stress, glucocorticoids and inflammation decrease it.

Most of what is known comes from rodents, where brain tissue can be sampled. In humans, BDNF is measured in serum or plasma, and here the field has a problem. Platelets store large amounts of BDNF and release it during clotting, so serum values reflect platelet content as much as anything; plasma values are lower and more variable. Whether either tracks brain BDNF is unresolved. Peripheral BDNF changes are therefore best treated as signals that something systemic happened, not as readouts of hippocampal neurotrophin signaling.

Where peptides enter

BDNF itself is not a practical research compound for whole-animal work: it is a 27 kDa dimeric protein with a short half-life that does not cross the blood–brain barrier. The peptide research community has approached the pathway from two directions.

Peptides that regulate BDNF expression

The best-documented example is Semax, a stabilized fragment of ACTH(4-10). Dolotov and colleagues reported that intranasal Semax in rats increased BDNF protein and TrkB mRNA in the hippocampus within hours of administration,⁵ and Shadrina and colleagues had earlier shown rapid induction of BDNF and NGF mRNA in cultured rat glia.⁶ Time-course studies found the response differed by region, with hippocampus responding more consistently than frontal cortex or retina.⁷ The induction of both ligand and receptor is what makes the Semax data interesting to neurotrophin researchers; a rise in BDNF alone can be buffered by receptor downregulation. What the mechanism is remains unknown, no receptor for Semax has been cloned, and the effect on behavior or structure downstream of the expression change is much less studied. Details are in Semax: A Review of Neuropeptide Research.

TrkB agonists

The other strategy bypasses BDNF and activates the receptor directly. In 2010 Jang and colleagues identified 7,8-dihydroxyflavone, a small flavonoid, as a selective TrkB agonist that triggered receptor phosphorylation, protected cultured neurons from apoptosis and reduced neuronal loss in mouse injury models.⁸ It is not a peptide, but it has become the standard positive control for TrkB activation, and peptide TrkB agonists and BDNF-mimetic cyclic peptides have been designed on the same principle. None has reached clinical development.

Preclinical vs. clinical evidence for BDNF modulation

Intervention	Evidence type	Tissue measured	Principal finding
Exercise	Human RCTs, meta-analysis4	Serum/plasma	Acute rise, larger with training
Val66Met genotype	Human genetics, imaging2,3	Cognitive testing, fMRI	Met carriers show reduced memory performance
Antidepressants, ketamine	Rodent and post-mortem1	Hippocampus, cortex	Increased BDNF expression
Semax	Rodent, cell culture5,6,7	Hippocampus, basal forebrain, glia	Increased BDNF and TrkB within hours
7,8-DHF	Cell culture, mouse8	Neurons, injury models	Direct TrkB activation, reduced neuron loss

Open questions for peptide researchers

The BDNF field offers peptide researchers well-defined assays, TrkB phosphorylation, CREB activation, BDNF and TrkB transcript levels, dendritic spine counts, and a clear set of unresolved questions. Does raising BDNF expression pharmacologically produce the same downstream effects as activity-dependent release, or does the spatial and temporal precision of the latter matter? Do peptides that induce BDNF also shift the pro-BDNF to mature BDNF ratio, and in which direction? Can the rodent findings for compounds such as Semax be reproduced by independent laboratories using modern quantitative methods? These are tractable in vitro and preclinical questions, and they are where research-grade material has a legitimate role. The broader neuroprotection landscape into which they fit is mapped in Neuroprotective Peptides: An Overview.

Cellular Energy & Neuro Research Semax 10 mg View listing →

Frequently asked questions

What does BDNF do in the brain?

BDNF supports neuronal survival, promotes dendritic and synaptic growth, and is required for the late phase of long-term potentiation that underlies memory formation. It signals through the TrkB receptor via the PI3K–Akt, MAPK/ERK and PLCγ pathways, and its own transcription is driven by activity through CREB.

What is the difference between pro-BDNF and mature BDNF?

Pro-BDNF is the precursor protein; mature BDNF is produced by proteolytic cleavage. Mature BDNF acting on TrkB promotes growth and potentiation, while pro-BDNF acting on p75 and sortilin promotes synaptic weakening and can trigger apoptosis. The two forms have opposing effects, so the ratio matters.

Does Semax increase BDNF?

In rats, intranasal Semax increased BDNF protein and TrkB expression in the hippocampus within hours, and it induced BDNF and NGF mRNA in cultured glial cells. These are animal and in vitro findings from a limited number of laboratories; there is no human brain data.

Is blood BDNF a good measure of brain BDNF?

Not reliably. Serum BDNF largely reflects platelet stores released during clotting, and plasma levels are variable. Whether either tracks central BDNF signaling is unresolved, so peripheral measurements should be interpreted cautiously.

What is the BDNF Val66Met polymorphism?

It is a common variant that replaces valine with methionine in the BDNF pro-domain, impairing activity-dependent secretion. Carriers show modestly reduced episodic memory performance and altered hippocampal activation in imaging studies. It is one of the clearest human demonstrations that BDNF handling affects cognition.

References & further reading

1. Bathina S, Das UN. Brain-derived neurotrophic factor and its clinical implications. Arch Med Sci. 2015;11(6):1164–1178. doi:10.5114/aoms.2015.56342 / PMID 26788077
2. Egan MF, Kojima M, Callicott JH, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003;112(2):257–269. doi:10.1016/S0092-8674(03)00035-7
3. Hariri AR, Goldberg TE, Mattay VS, et al. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci. 2003;23(17):6690–6694. PMID 12890761
4. Szuhany KL, Bugatti M, Otto MW. A meta-analytic review of the effects of exercise on brain-derived neurotrophic factor. J Psychiatr Res. 2015;60:56–64. doi:10.1016/j.jpsychires.2014.10.003 / PMID 25455510
5. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54–60. doi:10.1016/j.brainres.2006.07.108 / PMID 16996037
6. Shadrina MI, Dolotov OV, Grivennikov IA, et al. Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog. Neurosci Lett. 2001;308(2):115–118. PMID 11457573
7. Dmitrieva VG, Povarova OV, Skvortsova VI, et al. Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. J Mol Neurosci. 2010;41(1):30–35. doi:10.1007/s12031-009-9270-z
8. Jang SW, Liu X, Yepes M, et al. A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proc Natl Acad Sci U S A. 2010;107(6):2687–2692. doi:10.1073/pnas.0913572107 / PMID 20133810